Blinatumomab

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Relapsed/Refractory Philadelphia Positive B-precursor ALL

Conditions

Relapsed/Refractory Philadelphia Positive B-precursor ALL

Trial Timeline

Jan 3, 2014 → Jan 6, 2017

NCT ID

NCT02000427

About Blinatumomab

Blinatumomab is a phase 2 stage product being developed by Amgen for Relapsed/Refractory Philadelphia Positive B-precursor ALL. The current trial status is completed. This product is registered under clinical trial identifier NCT02000427. Target conditions include Relapsed/Refractory Philadelphia Positive B-precursor ALL.

What happened to similar drugs?

0 of 10 similar drugs in Relapsed/Refractory Philadelphia Positive B-precursor ALL were approved

Approved (0) Terminated (1) Active (9)

🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3

🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3

🔄Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3

❌Blinatumomab + Standard of Care ChemotherapyAmgenPhase 3

🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3

🔄Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Lenalidomide + Rituximab + Doxorubicin + Vincristine + Prednisone + BendamustineGilead SciencesPhase 3

🔄Odronextamab + Lenalidomide + RituximabRegeneron PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02187354	Pre-clinical	Completed	—	—	Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
NCT07192237	Phase 2	Recruiting	Feb 27, 2026	Oct 12, 2032	Phase 2 Study
NCT07134088	Phase 1/2	Recruiting	Dec 8, 2025	Jun 18, 2030	Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
NCT06649006	Phase 1	Completed	Jan 8, 2025	Dec 4, 2025	B-precursor Acute Lymphoblastic Leukemia
NCT06054113	Phase 2	Active	Jul 23, 2024	Oct 14, 2027	B Precursor Acute Lymphoblastic Leukemia
NCT04448834	Phase 2	Withdrawn	Jan 1, 2022	Jun 1, 2023	B-cell Acute Lymphoblastic Leukemia
NCT04506086	Approved	Terminated	Aug 26, 2021	Sep 16, 2024	B-precursor Acute Lymphoblastic Leukemia
NCT04746209	Phase 2	Recruiting	Feb 1, 2021	Dec 31, 2029	B-cell Acute Lymphoblastic Leukemia
NCT04521231	Phase 1/2	Recruiting	Jan 4, 2021	May 25, 2029	B Cell Precursor Acute Lymphoblastic Leukemia
NCT04556084	Phase 2	Terminated	Jan 1, 2021	Oct 1, 2022	B-cell Acute Lymphoblastic Leukemia
NCT04785547	Phase 2	Terminated	Dec 17, 2020	Jan 22, 2022	ALL, Childhood
NCT04044560	Phase 2	Terminated	Sep 8, 2020	Feb 2, 2022	B-cell Adult Acute Lymphoblastic Leukemia
NCT03751709	Phase 1	Completed	Feb 14, 2020	Nov 12, 2024	B-Cell Acute Lymphoblastic Leukaemia
NCT03298412	Phase 2	Terminated	May 23, 2018	Sep 30, 2019	High-risk Diffuse Large B-cell Lymphoma
NCT02961881	Phase 1	Completed	Sep 18, 2017	Sep 2, 2021	Non-Hodgkin's Lymphoma
NCT02910063	Phase 2/3	Completed	Jan 23, 2017	Mar 12, 2020	B-Cell Non Hodgkin Lymphoma
NCT02807883	Phase 2	Completed	Aug 1, 2016	Feb 1, 2022	Acute Lymphoblastic Leukemia
NCT02811679	Phase 2	Terminated	Aug 1, 2016	Dec 1, 2023	Non-Hodgkin Lymphoma
NCT02412306	Phase 1/2	Completed	Jun 4, 2015	Jul 4, 2019	Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia
NCT02000427	Phase 2	Completed	Jan 3, 2014	Jan 6, 2017	Relapsed/Refractory Philadelphia Positive B-precursor ALL

Competing Products

20 competing products in Relapsed/Refractory Philadelphia Positive B-precursor ALL

See all competitors

Product	Company	Stage	Hype Score
mRNA-2752 + Durvalumab	AstraZeneca	Phase 1	29
mRNA-2416	Moderna	Phase 2	0
agenT-797	MiNK Therapeutics	Phase 1	19
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	39
Eribulin mesylate	Eisai	Phase 2	35
Tirabrutinib + Rituximab + Temozolomide	Ono Pharmaceutical	Phase 3	47
Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab	Eli Lilly	Phase 1/2	36
ISB 1342	Glenmark Pharmaceuticals	Phase 1	29
SHR2554; Chidamide analog tablets + SHR2554 analog tablets; Chidamide	Jiangsu Hengrui Medicine	Phase 3	47
Linperlisib ； Rituximab	Jiangsu Hengrui Medicine	Phase 1/2	39
Epcoritamab + Epcoritamab, lenalidomide and rituximab	AbbVie	Phase 2	42
Etentamig	AbbVie	Phase 1	33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclax	AbbVie	Phase 3	40
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + Daratumumab	AbbVie	Phase 1	33
[14C]ABT-199 (GDC-0199)	AbbVie	Phase 1	21
ABT-199 + bortezomib + dexamethasone	AbbVie	Phase 1	29
Venetoclax + Dexamethasone	AbbVie	Phase 1/2	32
ABBV-453 + Dexamethasone + Daratumumab + Lenalidomide	AbbVie	Phase 1	33
AZD4573	AstraZeneca	Phase 2	35
Moxetumomab Pasudotox	AstraZeneca	Pre-clinical	26